Rapporteur Report – Track A Basic and Translational Sciences

Slides:

Advertisements

Similar presentations

T follicular helper cells in HIV infection

Advertisements

Measuring the latent HIV Reservoir

“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Pediatric HIV “Cure” HIV Cure Research Training Curriculum

Multi-Faceted Aspects of Acute HIV Infection Concluding remarks Tony Kelleher Kirby Institute & St Vincent’s Centre for Applied Medical Research.

EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.

Impact of Early Initiation of Combination Antiretroviral Therapy on Measures of Virus in Peripheral Blood of Vertically HIV-1-Infected Children Jason Brophy.

Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.

Measuring the latent HIV Reservoir

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.

HIV: Acute (Primary) Infection. David H

Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.

Persistent low-level viremia despite clinically successful antiretroviral therapy appears correlated with more frequent resting CD4+ T cell Infection NM.

Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.

HIV Cellular Pathogenesis III

Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.

Yerkes National Primate Research Center

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.

HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.

What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

Immune reconstitution Anjie Zhen, PhD

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:

SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.

Create a concept map of the adaptive immune system.

Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,

Conflict of Interest No conflicts of interest to declare.

The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.

Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,

Viral and Host characteristics of a child with perinatal HIV-1 after prolonged period of ART cessation in the CHER trial Avy Violari, Mark Cotton, Louise.

Walter + Eliza Hall Institute of Medical Research

State of HIV Cure Research

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

T and B Cell Development

HIV Cure: Current Status and Future Perspectives

No Conflicts of Interest to declare.

VL patient support: General education at different levels

Acute HIV infection and HIV cure

Hepatitis C virus in the human liver transplantation model

The block-and-lock approach

Follicular CD8+ T-cells (fCD8) in GALT are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during PHI John Thornhill Imperial.

Cepheid Symposium, IAS 23rd July 2018

HIV-1 specific restriction factors increase in response to viral rebound after analytical treatment interruption De Scheerder Marie-Angélique, Van Hecke.

Monique Nijhuis University Medical Center Utrecht, the Netherlands

Quantitative analysis of the latent reservoir during treatment interruption. Quantitative analysis of the latent reservoir during treatment interruption.

Cryptococcal Immune Reconstitution Inflammatory Syndrome

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,

Li Huang Duke University, North Carolina, USA

Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies?

Cryptococcal Immune Reconstitution Inflammatory Syndrome

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

Volume 158, Issue 5, Pages (August 2014)

Alex Sigal, David Baltimore Cell Host & Microbe

CD8+ T Cells and cART: A Dynamic Duo?

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Fig. 3 Viral loads and viral DNA in anti-α4β7 antibody–treated rhesus macaques that initiated ART during chronic SIVmac251 infection (study 2). Viral loads.

Fig. 2 Dynamics of Nef-stop repair and predictors of viral set-point.

Keep control: Elite and post-treatment controllers

Share your thoughts on this presentation with #IAS2019

Presentation transcript:

Rapporteur Report – Track A Basic and Translational Sciences Mathias Lichterfeld, M. D., Ph. D. Associate Professor of Medicine Brigham and Women’s Hospital Harvard Medical School no relevant conflicts of interest or other disclosures

The number of identical HIV-DNA sequence expansions increases over time in peripheral blood Lee/Palmer et al, Abstract MOAA0105

Defective proviruses can encode for HIV-1 protein Imamichi/Lane et al, Abstract MOPDA0102

HIV-specific CD8+ T cells in early treated subjects are more functionally competent Untreated IFN-gamma CD8 Tetramer Nkosi/Ndhlovu et al, Abstract TUAA0101

hetIL-15 Treatment Increases SIV-specific T Cells Within the Lymph Nodes CD8 CM9 Tetramer+ Untreated hetIL-15 0.3 2.5 CD3+ T lymphocytes in LN Tetramer+ Granzyme B Ki67 Expansion Cytotoxic Potential Valentin/Pavlakis et al, Abstract TUPDA0103

hetIL-15 Treatment Increases SIV-specific T Cells Within the Lymph Nodes germinal center Pre-ALT803 Post-ALT803 Webb/Sacha et al, Abstract TUPDA0104

Plasma viremia in SIV-infected NHP after treatment with ART and a4/b7 antibodies or control Fauci et al, Presentation MOSS0102

Viral control following a4b7 antibody infusion is Likely mediated by cellular immune responses Fauci et al, Presentation MOSS0102

Prolonged HIV-1 control after perinatal infection “The South African Baby” HIV-1 DNA detectable at 32 days of life Initiated AZT/3TC/LPV/r at 8.5 weeks of life Interrupted ART after 40 weeks 3-monthly f/u Undetectable VL after 8.75 years off ART on stored and current specimens No protective HLA class I alleles Weak HIV-specific T/B cell responses 5 HIV DNA copies/ million CD4 T cells VOA negative x2 Violari/Tiemessen et al, Abstract TUPDB0106LB

Delayed viral rebound after treatment during hyperacute HIV-1 infection Participant A: Underwent ATI after 34 months of ART Latent reservoir size ≈200 cells prior to ATI ≈1% of individuals with a similar HIV burden may achieve lifelong ART-free remission Henrich/Deeks et al, Abstract TUPDB0103

Effects of therapeutic vaccination in ART-treated HIV patients on viral rebound kinetics Fauci et al, Presentation MOSS0102

Therapeutic vaccination has no effect on viral rebound kinetics or viral reservoir markers Fauci et al, Presentation MOSS0102

Viral reservoir biomarkers represent predictors of viral rebound kinetics Fauci et al, Presentation MOSS0102

Many thanks! Nancie Archin, PhD Univ of North Carolina, Chapel Hill Anni Winckelman, MD Univ of Aarhus, Denmark Caroline Pereira Bittencourt Passes, PhD Institute Pasteur, Paris